|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2000-2-7
|
|
pubmed:abstractText |
The adhesion molecule L-selectin (CD62L) mediates lymphocyte recirculation and leucocyte rolling on vascular endothelium at sites of inflammation. Serum levels of soluble L-selectin (sL-selectin) were measured in patients with SLE in order to relate these levels to clinical activity and immunological parameters. An ELISA was used to detect the soluble form of human L-selectin (CD62L) in 42 patients with SLE and in 33 healthy individuals. The mean +/- s.e.m. values of sL-selectin were 1285 +/- 121 ng/ml for patients with SLE and 986 +/- 180 ng/ml for healthy blood donors, but there was no significant difference. When patients with active SLE were analysed, higher levels of circulating sL-selectin were found when compared with patients without activity (1497 +/- 167 ng/ml versus 941 +/- 150 ng/ml; P = 0.028). We found a significant correlation between the levels of sL-selectin and of dsDNA antibodies (r = 0.36, P = 0. 044) and between levels of sL-selectin and SLE Disease Activity Index (SLEDAI) score (r = 0.42, P = 0.003). Patients with active SLE studied cross-sectionally showed significant elevations of sL-selectin (CD62L) compared with controls. Thus, the levels of this soluble adhesion molecule correlated with active disease and levels of anti-dsDNA antibodies.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-1279685,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-1385536,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-1599520,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-1974032,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-2107799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-3652514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-3813670,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7138600,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7507411,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7510492,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7519859,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7522621,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7522685,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7533494,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7534203,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7539045,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7542213,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7542571,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7543141,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7543387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7582719,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7681283,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7687701,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7848308,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-7876564,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-8099860,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-8102057,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-8479324,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-8607904,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-8857959,
http://linkedlifedata.com/resource/pubmed/commentcorrection/10606979-9218616
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0009-9104
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
119
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
169-74
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10606979-Adolescent,
pubmed-meshheading:10606979-Adult,
pubmed-meshheading:10606979-Antibodies, Antinuclear,
pubmed-meshheading:10606979-Case-Control Studies,
pubmed-meshheading:10606979-Child,
pubmed-meshheading:10606979-Cross-Sectional Studies,
pubmed-meshheading:10606979-Female,
pubmed-meshheading:10606979-Follow-Up Studies,
pubmed-meshheading:10606979-Humans,
pubmed-meshheading:10606979-L-Selectin,
pubmed-meshheading:10606979-Lupus Erythematosus, Systemic,
pubmed-meshheading:10606979-Male,
pubmed-meshheading:10606979-Middle Aged,
pubmed-meshheading:10606979-Reference Values,
pubmed-meshheading:10606979-Solubility,
pubmed-meshheading:10606979-Time Factors
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Increased serum levels of soluble L-selectin (CD62L) in patients with active systemic lupus erythematosus (SLE).
|
|
pubmed:affiliation |
Systemic Autoimmune Diseases Unit, Department of Cellular Biology, University of Barcelona, Spain. font@medicina.ub.es
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
